Virtual reality surgical training wins industry attention with scalable model

Tern plc

A virtual reality training platform developed by Fundamental XR and Orbis International has been awarded Gold in a major technology competition, highlighting how immersive tools are starting to gain traction in global medical education.

This programme, focused on ophthalmic surgery, allows medical trainees to practise procedures in a fully immersive virtual environment, without the limitations of physical equipment, live supervision or real-world patient risk. The result is a more accessible, standardised form of surgical education, especially valuable in countries where hospital training resources are limited or overstretched.

What sets this initiative apart is its focus on real-world application. The technology has been designed to fit the workflow and constraints of medical education systems in lower-resource settings. This combination of technical quality and real-world relevance is what earned the recognition, and it signals a step forward for VR in professional training markets.

Orbis brings decades of experience in eye care and surgical training around the world, while Fundamental XR provides the technical capability to deliver high-fidelity, scalable simulations. Together, they have built a tool that solves a pressing educational problem with modern technology, a clear use case with long-term potential.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Search